Full-year revenue growth: Mid-teens
Management indicated they may be 'more towards mid-teens rather than early teens' after Q1's strong performance, vs. earlier guidance. Formal guidance update expected after Q2.
LALPATHLAB / guidance tracker
Keep management guidance in view.
Dr. Lal Path Labs · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
EBITDA margin guidance: 27-28% maintained
Management retained the annual margin guidance but noted CGHS pricing benefits will sustain for 2-3 quarters and emphasized reinvestment strategy over margin expansion.
Lab expansion: 12-15 labs in FY27
Same pace as FY26 additions, with continued focus on radiology centers (3-4 planned) and Suburban brand investments in West India to accelerate growth trajectory.
International expansion: 3-5 year horizon
Wholly owned subsidiary in Dubai operational; Africa, Middle East, CIS, and Southeast Asia identified as focus markets with no near-term revenue targets set.
FY26 organic revenue growth of 11-12%
Management reiterated confidence in delivering 11-12% organic revenue growth for the full fiscal year.
FY26 EBITDA margin of 27-28%
Management guided for EBITDA margin between 27-28% for FY26, despite GST pass-through and labor code impact.
Capex of ₹150-160 crore for FY26
Capex for FY26 expected at ₹150-160 crore, including investments in radiology centers and precision diagnostic center.
No price increase for next 2-3 quarters
Management stated no price increase is expected for at least 2-3 quarters after passing on GST benefits.